Supplements

Supplements currently available include:

Clusters of cardiovascular risk – a Pandora’s box
Proceedings from the Takeda sponsored Symposium, Diabetes UK, 28th March 2006
Volume 6, Supplement 2, September-October 2006

Evolving treatment paradigms for vascular risk reduction in type 2 diabetes
Volume 6, Supplement 1, March-April 2006

Role of nicotinic acid in raising high-density lipoprotein cholesterol (HDL-C) to reduce cardiovascular risk: an Asian/Pacific consensus
Volume 5, Supplement 2, September-October 2005

Insulin resistance and novel markers of cardiovascular disease in type 2 diabetes
Volume 2, Supplement 3, September-October 2002

Dyslipidaemia and the metabolic syndrome: critical issues in improving CVD risk reduction
Volume 5, Supplement 1, July-August 2005

Dual inhibition of cholesterol absorption and cholesterol synthesis - a new class in cholesterol management
Volume 4, Supplement 1, January-February 2004

Time2Take on risk - making the link between insulin resistance and cardiovascular risk
Volume 3, Supplement 2, May-June 2003

Pre-diabetes - to treat or not to treat and with what? Implications for current practice
Volume 3, Supplement 1, May-June 2003

Time2Take on Risk
Volume 2, Supplement 2, May-June 2002

Will the treatment of insulin resistance reduce cardiovascular disease?
Proceedings from a symposium on the occasion of the 37th Annual Meeting of the EASD
Volume 2, Supplement 1, January-February 2002